Gastrointestinal Agents

Displaying 1 - 2 of 2CSV
Lamichhane, N., Melas, N., Bergqvist, V., Ekholm, N.-P., Olén, O., Ludvigsson, J. F., Hjortswang, H., Marsal, J., Eriksson, C., & Halfvarson, J. (2024). Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease. Digestive Diseases and Sciences, 69(6), 2175–2183. https://doi.org/10.1007/s10620-024-08422-9
Publication Date
Travis, S., Silverberg, M. S., Danese, S., Gionchetti, P., Löwenberg, M., Jairath, V., Feagan, B. G., Bressler, B., Ferrante, M., Hart, A., Lindner, D., Escher, A., Jones, S., & Shen, B. (2023). Vedolizumab for the Treatment of Chronic Pouchitis. New England Journal of Medicine, 388(13), 1191–1200. https://doi.org/10.1056/nejmoa2208450
Publication Date